VIDEO: Oral drug regimen well tolerated in older patients with multiple myeloma

ByHenry Chi Hang Fung, MD, FACP, FRCPE

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.

The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with relapsed refractory disease.

“It’s very interesting that patients can tolerate it well even when they are very frail,” said Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center.

Reference:

Costa LJ, et al. Abstract 7504. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Fung reports serving on the speakers’ bureau of AstraZeneca, Incyte and Johnson and Johnson.

Take Homes in Multiple Myeloma

Read more

VIDEO: Oral drug regimen well tolerated in older patients with multiple myeloma

Reference:

Related Content